Muñoz‐Rodríguez 2021.

Study characteristics
Notes	English title Characteristics and risk factors associated with mortality in a multicenter Spanish cohort of patients with COVID‐19 pneumonia Study setting Start of study recruitment (MM/YYYY) 02/2020 End of study recruitment (MM/YYYY) 05/2020 Study design prospective cohort Study centre(s) multiple centres/clinics/areas within a country Number of centres/clinics/areas 14 Study setting outpatient and inpatient Number of participants recruited 12,126 Sampling method consecutive participants Participants Female participants (absolute number), 5667 Age measure, value mean (standard deviation), 66.4 (17.3) Inclusion criteria Participants were adult patients (> 18 years old) transferred between hospitals or attended in the referral hospital, meeting one or more laboratory criteria and/or one or more clinical criteria of suspected COVID‐19. Exclusion criteria Non‐criteria inclusion for patients, subsequent admissions, transfers or duplicates for the same patient, and paediatric patient (< 18 years old) were excluded in our study. Smoking NR Diabetes NR Hypertension (absolute number), 6276 Cardiovascular diseases (absolute number), 3006 Please indicate if additional information is available  with respect to cardiac pathology Asthma NR Chronic obstructive pulmonary disease NR Other pulmonary diseases (absolute number), 2735 Please indicate if additional information is available  with respect to respiratory pathology Immunosuppression NR Please indicate if additional information is available NR Chronic kidney disease NR Cancer NR Steroid administration (absolute number), 4785 Supplemental oxygen (absolute number), 1294 Differential values for various oxygenation methods (if indicated) Invasive ventilation = 530, non‐invasive ventilation = 764 Other treatment absolute number Dose if applicable Antiretroviral treatment included 100 mg lopinavir/25 mg ritonavir, 200 mg emtricitabine/245 mg tenofovir disoproxil or 800 mg darunavir/150 mg cobicistat Duration if applicable NR Percentage received this treatment in absolute number, antiretroviral treatment = 3337; chloroquine = 7910; interferon B‐1b = 292; azithromycin = 7741; tocilizumab = 370 Prognostic factor(s) Study’s definition for obesity NR The time when obesity has been measured unspecified Main variable used for determination of obesity other (please specify) Threshold used for definition of obesity  NR Measure of frequency absolute number Frequency value 2100 How many eligible outcomes reported? 1 How many eligible outcomes reported? 1 Outcome(s) mortality Outcome (prognostic factor) Mortality (obesity) Outcome Mortality Prognostic factor (category):  Obesity Follow‐up Number of patients followed completely for this outcome  12,126 Number of obese patients followed completely for this outcome  2100 Number of non‐obese patients followed completely for this outcome  9086 Univariable (unadjusted) analysis for obesity Effect measure for obesity NR Effect measure value (95% CI) NR Multivariable (adjusted) analysis for obesity Modelling method logistic regression The set of prognostic factors used for adjustment sex, age, HBP, cardiac pathology, respiratory pathology, obesity, symptoms, clinical features, treatment Effect measure for obesity odds ratio  Effect measure value (95% CI) 1.3 (1.1, 1.5)
Item	Authors' judgement	Support for judgement
Study Participation	Yes	Appendix 3
Study Attrition Mortality	Yes	Appendix 3
Prognostic Factor Measurement	No	Appendix 3
Outcome Measurement Mortality	Yes	Appendix 3
Confounding Bias Mortality	No	Appendix 3
Statistical Analysis Bias	Unclear	Appendix 3